| Industry | 制造业 | ||||||||||||||||||||||||
| Company Introduction | 公司是一家聚焦多肽药物及小分子化药进行自主研发与定制研发生产相结合的生物医药企业。在高级医药中间体、原料药到制剂的各个领域，公司积极进行产品研发和业务拓展，逐步形成了以定制类产品及技术服务业务为主要收入来源、自主选择产品业务收入及占比快速增长的发展格局。 在定制类产品及技术服务方面，公司利用较强的研发与合成能力在艾滋病、肿瘤、关节炎等多个重大疾病领域，采用定制研发+定制生产的方式，每年为全球创新药企的30多个创新药研发项目提供高级医药中间体或原料药的定制研发生产服务（CDMO），解决其创新药品研发过程中的技术瓶颈、生产工艺路径优化及放大生产等难题，有效提高下游客户新药研发效率，降低其新药研发生产成本。公司这类业务客户包括美国因赛特（Incyte）、美国吉利德（Gilead）、德国勃林格殷格翰（Boehringer Ingelheim）、美国福泰制药（Vertex）、前沿生物、硕腾（Zoetis）等数十家国内外知名创新药企。 在自主选择产品方面，公司围绕糖尿病、心血管疾病、肿瘤等疾病治疗方向，以多肽药物为主、以小分子化药为辅，自主选择具有较高技术壁垒和良好市场前景的仿制药药品（包括原料药及制剂），积极组织研发、生产、注册申报和销售。公司自主研发产品已搭建了丰富的产品管线，完成了18种仿制药原料药及制剂的研发布局，产品管线涵盖利拉鲁肽、索玛鲁肽、苯甲酸阿格列汀、依替巴肽、醋酸兰瑞肽、磷酸奥司他韦、胸腺法新等知名品种。截至本招股意向书签署日，公司已取得药品注册批件2项，8个原料药品种获得境内原料药登记，8个原料药品种获得美国FDA药品DMF编号。公司自主开发的原料药已销往韩国大熊制药（Daewoong）、印度西普拉（Cipla）、印度卡迪拉（Cadila）、以色列梯瓦制药（Teva）、印度雷迪博士实验室（Dr.Reddy）、普利制药、齐鲁制药、健友股份等数十家国内外知名制药公司。除上述仿制药原料药及制剂产品外，公司也已在多肽类创新药领域积极进行研发布局，其中公司正在研发的一项GLP-1受体单靶点激动剂1类新药，目前处于临床前研究阶段。 在研发与技术方面，公司拥有一支由中科院“百人计划”专家等多位知名专家领衔的国际化高水平研发团队，成立了三个省级研发中心，建立了多肽规模化生产技术平台、手性药物技术平台、绿色工艺技术平台、制剂给药技术平台、多肽类新药研发技术平台等五大核心技术平台。围绕多肽药物与小分子化药的特性和技术难点，经过多年技术创新发展，公司解决了多肽药物及小分子化药研发及合成生产过程中的多项重要技术难题。在小分子化药领域，公司能够自主完成各种复杂高难度化合物的生产工艺研究，解决药品生产过程中的技术瓶颈、优化工艺路径，尤其是在手性药物技术和绿色工艺技术方面，公司掌握了一系列先进的核心技术，能够为全球创新药企提供高效率、高质量、低成本、大规模且绿色环保的中间体或原料药生产服务；在多肽药物合成领域，公司将传统多肽固相合成和小分子液相合成技术进行融合，突破了长链多肽药物规模化大生产的技术瓶颈，具备了侧链化学修饰多肽、长链修饰多肽数公斤级的大生产能力，如利拉鲁肽、艾博韦泰等长链修饰多肽药物的单批次产量已超过 5 公斤，达到行业先进水平。截至目前，公司共拥有 77 项专利，其中发明专利 36 项，该等专利技术支撑了公司主营业务快速增长。 | ||||||||||||||||||||||||
| Main Business | 公司是一家聚焦多肽药物及小分子化药进行自主研发与定制研发生产相结合的生物医药企业。 | ||||||||||||||||||||||||
| Legal Representative | 童梓权 | ||||||||||||||||||||||||
| Top Executives |
|
||||||||||||||||||||||||
| Top 5 Shareholder |
|
||||||||||||||||||||||||
| Company Secretary | 周骅 | ||||||||||||||||||||||||
| Solicitors | 国浩律师（杭州）事务所 | ||||||||||||||||||||||||
| Auditors | 中天运会计师事务所（特殊普通合伙） | ||||||||||||||||||||||||
| Tel No | 0571-86297893 | ||||||||||||||||||||||||
| Fax No | 0571-86298631 | ||||||||||||||||||||||||
| Website | www.sinopep.com.cn | ||||||||||||||||||||||||
| ir@sinopep.com | |||||||||||||||||||||||||
| Company Address |
|
||||||||||||||||||||||||
| Listing Date | 20/05/2021 | ||||||||||||||||||||||||
| Shares Capital |
|
||||||||||||||||||||||||
| EPS(RMB)* | ¥ 0.760 | ||||||||||||||||||||||||
| DPS(RMB)* | ¥ 0.400 | ||||||||||||||||||||||||
| NBV Per Share(RMB)* | ¥ 9.519 | ||||||||||||||||||||||||
| Market Capitalization(RMB) | 11.123B |
 |
Only Chinese content is avaliable |
|
N
/
N
: Eligible Stock for SH-HK Northbound trade (For all investors/ For institutional professional investors only)
N
: Eligible Stock for SH-HK Ex-Northbound trade (sell only)
|
|
|
N
/
N
: Eligible Stock for SZ-HK Northbound trade (For all investors/ For institutional professional investors only)
N
: Eligible Stock for SZ-HK Ex-Northbound trade (sell only)
|
|
| * | Unadjusted Data |
| Information provided by: etnet | ||
| Terms and Conditions | ||
| Risk Disclosure: |
| The prices of securities may fluctuate, sometimes dramatically. The price of a security may move up or down, and may become valueless. It is as likely that losses will be incurred rather than profit made as a result of buying and selling securities. The information is for reference only, it does not constitute any offer, solicitation, recommendation, comment or any guarantee to the purchase or sale of any investment product or service. Customers should not make any investment decisions based on this information alone. |
| Disclaimer: |
| This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Chiyu Banking Corporation Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information. |